Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression

Menopause

Volumn 15, Issue 3, 2008, Pages 442-453

  Tanaka, Yoshihiro ^a   Kato, Kiyoko ^b   Mibu, Ryuichi ^a   Uchida, Souko ^a   Asanoma, Kazuo ^b   Hashimoto, Kazunori ^a   Nozaki, Masahiro ^a   Wake, Norio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Colon cancer; Cyclin E; Medroxyprogesterone acetate; p21WAF1 CIP1

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; MEDROXYPROGESTERONE ACETATE; P21 ACTIVATED KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER RISK; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; COLON CANCER; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; WESTERN BLOTTING;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; PROGESTINS;

EID: 43249084505     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318156fb77     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Potten CS. Epithelial cell growth and differentiation. II. Intestinal apoptosis. Am J Physiol 1997;273:G253-G257.
3. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
4. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-1659.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. 1-phase progression. Genes Dev 1999;313:1501-1512.
7. Edgar BA, Orr-Weaver TL. Endoreplication cell cycles: more for less. Cell 2001;105:297-306.
8. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219.
9. Hunter T. Braking the cycle. Cell 1993;75:839-841.
10. Fischer PM, Lane DP. Inhibitors of cyclin-dependent kinases as anticancer therapeutics. Curr Med Chem 2000;7:1213-1245.
11. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483-493.
12. Baron JA, Sandler RS, Haile RW, Mandel JS, Mott LA, Greenberg ER. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst 1998;90:57-62.
13. Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S. Food groups and colorectal cancer risk. Br J Cancer 1999;79:1283-1287.
14. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
15. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004.
16. Yagi H, Miyamoto S, Tanaka Y, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005;92:1737-1745.
17. Jinno S, Hung SC, Yamamoto H, Lin J, Nagata A, Okayama H. Oncogenic stimulation recruits cyclin-dependent kinase in the cell cycle start in rat fibroblast. Proc Natl Acad Sci U S A 1999;96:13197-13202.
18. Jinno S, Hung SC, Okayama H. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4. Oncogene 1999;18:565-571.
19. Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996;15:7060-7069.
20. Horwitz KB, Freidenberg GR. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47Dco human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res 1985;45:167-173.
21. Terakawa N, Hayashida M, Shimizu I, et al. Growth inhibition by progestins in a human endometrial cancer cell line with estrogenin-dependent progesterone receptors. Cancer Res 1987;47:1918-1923.
22. Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 1978;62:499-504.
23. Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 1988;48:5084-5091.
24. Campio L, Robustelli Della Cuna G, Taylor RW, eds. Role of Medroxyprogesterone in Endocrine-Related Tumors, 2. New York: Raven Press, 1983:1-216.
25. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283.
26. Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 1980;40:2557-2561.
27. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 1995;13:1352-1357.
28. Buchanan G, Birrell SN, Peters AA, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 2005;65:8487-8496.
29. Lillie EO, Bernstein L, Ingles SA, et al. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res 2004;64:1237-1241.
30. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor " mediated system. Cancer Lett 2000;161:63-71.
31. Geelhoed GW, Alford C, Lippman ME. Biologic implications of steroid hormone receptors in cancers of the colon. South Med J 1985;78:252-254.
32. Korenaga D, Orita H, Okuyama T, et al. Sex hormone receptor-negative tumors have a higher proliferative activity than sex hormone receptor-positive tumors in human adenocarcinomas of the gastrointestinal tract. Surg Today 1998;28:1007-1014.
33. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999;13:376-384.
34. Lu S, Jenster G, Epner DE. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 2000;14:753-760.
35. Rossi R, Zatelli MC, Valentini A, et al. Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J Endocrinol 1998;159:373-380.
36. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006;66:1329-1338.